Griswold Dp
Impact in
- Oncology top 5%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 11
- Cancer Treatment and Pharmacology 4
- Cancer Cells and Metastasis 3
-
- Cancer therapeutics and mechanisms 6
- Glycosylation and Glycoproteins Research 1
- Co-authors
- Schabel Fm (12 shared papers)Laster Wr (9 shared papers)Corbett Th (8 shared papers)Trader Mw (5 shared papers)Skipper He (5 shared papers)Linda Simpson‐Herren (4 shared papers)Wilcox Ws (2 shared papers)Emil Frei (1 shared paper)
- Journals
- Cancer Research (1 paper)PubMed (19 papers)
- Partner nations
- United States
In The Last Decade
Griswold Dp
20 papers receiving 812 citations
Griswold Dp's Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 498
- Cancer Research 107
- Hematology 64
- Reproductive Medicine 47
- Pulmonary and Respiratory Medicine 174
Countries citing papers authored by Griswold Dp
This map shows the geographic impact of Griswold Dp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Griswold Dp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Griswold Dp more than expected).
Fields of papers citing papers by Griswold Dp
This network shows the impact of papers produced by Griswold Dp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Griswold Dp. The network helps show where Griswold Dp may publish in the future.
Co-authors
The 9 scholars most cited alongside Griswold Dp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Hit paper breakdown → | 1980 | 394 |
| 2 | Establishment of cross-resistance profiles for new agents. | 1983 | 126 |
| 3 | Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. | 1978 | 91 |
| 4 | Concepts for controlling drug-resistant tumor cells. | 1980 | 46 |
| 5 | Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755. | 1969 | 45 |
| 6 | Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. | 1965 | 44 |
| 7 | Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. | 1982 | 41 |
| 8 | Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. | 1968 | 34 |
| 9 | Toxicity studies in mice treated with 1-beta-D-arabinofuranosylcytosine (ara-C). | 1969 | 32 |
| 10 | Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents. | 1972 | 31 |
| 11 | Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. | 1987 | 25 |
| 12 | Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. | 1979 | 24 |
| 13 | Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. | 1990 | 22 |
| 14 | Altered sensitivity of a hamster plasmacytoma to cytosine arabinoside (NSC-63878). | 1970 | 20 |
| 15 | Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence. | 1986 | 12 |
| 16 | Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure. | 1981 | 11 |
| 17 | Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia. | 1987 | 11 |
| 18 | Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo. | 1990 | 3 |
| 19 | Approaches to combination chemotherapy in rat, mouse, and hamster tumors. | 1974 | 3 |
| 20 | Studies of the growth, population kinetics, and host lethality of CD8F mammary adenocarcinoma. | 1978 | 1 |
About Griswold Dp
Griswold Dp is a scholar working on Oncology, Molecular Biology, Organic Chemistry, Genetics and Pulmonary and Respiratory Medicine, having authored 20 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (6 papers), Cancer Treatment and Pharmacology (4 papers), Cancer Cells and Metastasis (3 papers), Quinazolinone synthesis and applications (2 papers), Synthesis and biological activity (2 papers), Multiple Myeloma Research and Treatments (2 papers), Click Chemistry and Applications (1 paper) and Glycosylation and Glycoproteins Research (1 paper). The work is most often cited by research in Oncology (498 citations), Cancer Research (107 citations), Hematology (64 citations), Reproductive Medicine (47 citations) and Pulmonary and Respiratory Medicine (174 citations). Griswold Dp has collaborated with scholars based in United States. Frequent co-authors include Schabel Fm, Laster Wr, Corbett Th, Trader Mw, Skipper He, Linda Simpson‐Herren, Wilcox Ws, Emil Frei and WP Peters. Their work appears in journals such as Cancer Research and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.